Amid a raft of federal changes cutting funding and capacities at the Food and Drug Administration, investors are soon ...

The group had a bad week after turmoil at the FDA, continuing a long period of underperformance following the pandemic.

However, in the later stages of the pandemic, demand for the product declined, and Moderna shifted to a loss. For example, ...

As director of the FDA's Center for Biologics Evaluation and Research, Marks has publicly supported programs that expedited ...

Biotech stocks skidded again Tuesday as "chaos" reigned at the FDA with reports of mass firings, including the departure of a ...

The decline in biotech stocks comes after FDA official Peter Marks' resignation, citing irreconcilable differences with the ...

Shares of early-stage biotech stocks, including Biohaven ( BHVN -6.50%), Recursion Pharmaceuticals ( RXRX -7.37%), and CRISPR ...

Biotech investors are reeling after the sudden departure of Peter Marks, a pivotal figure in the U.S. Food and Drug ...

The FDA has set back Aldeyra Therapeutics’ ambitions to win approval for its dry eye disease, rejecting its second ...

On The Readout LOUD podcast, STAT reporters talk about new FDA commissioner Marty Makary's first week amid a swirl of layoffs ...

In this week’s edition of InnovationRx, we look at Trump's massive health agency layoffs, Palantir’s trade secret lawsuit, ...

Biotech stocks took a hit after the sudden resignation of Dr. Peter Marks, head of the FDA’s Center for Biologics Evaluation ...